TherOx will feature its SuperSaturated Oxygen Therapy, designed to ameliorate progressive myocardial necrosis by minimizing miscrovascular damage in heart attack patients following percutaneous coronary intervention (PCI).
The system is reportedly the first entrant in a new treatment category for acute myocardial infarction patients. SuperSaturated Oxygen Therapy refers to the creation and focal delivery of SuperOxygenated arterial blood directly to reperfused areas of myocardial tissue that may be at risk. The net effect is to potentially reduce infarct size and salvage heart muscle.
The system is CE Marked, but only limited to investigational use in the U.S.